ClinicalTrials.gg
CompletedNCT00654940Updated Feb 9, 2021Results posted

A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients

A Phase 1 interventional study of Pregabalin (Lyrica) and Placebo in Nerve Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-09.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Enrollment
45th of 50
25 · median 109
Started
2008
with 3 others
Phase 1
3 of 50
none open now
Registered
13th of 50
by date
Lead sponsor
12 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing pregabalin in Neuralgia, this one is the 45th largest by enrollment, is one of 4 that started in 2008, is one of 3 in phase 1, and was the 13th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Neuralgia studies recruiting now, 78 (51%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

The purpose of this study is to assess whether a cross-over type study design in post-traumatic neuropathic patients can be used to assess the activity of potential analgesic agents

Read the detailed description

Methodology study to evaluate a cross-over study design in post-traumatic neuropathic pain patients.

03

Conditions studied

  • Nerve Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients require a diagnosis of post-traumatic peripheral neuropathic pain (NeP), including post-surgical NeP and NeP due to peripheral nerve injury, which has lasted at least 3 months following the traumatic event.
  • Patients during the screening week must have completed ≥ 4 daily pain scores and have an average daily pain score ≥ 4.
  • Female patients of must have a negative urine pregnancy test at Screening and be practicing an acceptable form of .

Exclusion criteria

Exclusion Criteria:

  • Patients with neuropathic pain (NeP) that is not due to trauma; e.g. patients with trigeminal neuralgia, central pain, complex region pain syndrome type I, phantom limb pain, radiculopathy, painful diabetic neuropathy or post-herpetic neuralgia or patients with any other co-existing pain which cannot be differentiate from NeP of peripheral origin.
  • Patients who have previously failed to respond to pregabalin at a total daily dose of equal to or greater than 300 mg or are intolerant to those doses.
  • Patients who have previously failed to respond to gabapentin at a total daily dose of equal to or greater than 1800 mg.
  • Patients with any type or history of , except either where there has been no ongoing treatment for at least 6 months or all basal cell carcinomas; all patients with a history of brain or spinal tumors will be excluded.
  • Patients who currently have ongoing litigation related to any injury affecting their pain symptomatology.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    A

    Drug: Pregabalin (Lyrica)

  • Placebo comparator
    B

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Treatment Week 2 in Daily Pain Rating Scale

    Daily Pain Rating Scale by treatment and sequence using an 11-point Likert scale: range 0 (no pain) to 10 (worst possible pain) over the past 24 hours. Self-assessment was performed daily on rising from bed (for the final time in the case of interrupted sleep). Average daily pain score: mean of the previous 7 days daily pain scores. Baseline was defined as the mean of the last 7 pre-treatment pain scores for each period. End of treatment was defined as the mean of the last 7 on treatment pain scores for each period.

    Time frame: Week 0 to Week 2, Week 4 to Week 6 (Baseline to Week 2 [End of Treatment] for each treatment period)

Secondary outcomes

  1. Neuropathic Pain Symptom Inventory (NPSI)

    NPSI at end of treatment: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.

    Time frame: Week 0 to Week 2, Week 4 to Week 6 (Baseline to End of Treatment in Treatment Periods 1 and 2)

  2. Subject Activity as Captured by the Actiwatch Score Device: Total Activity Score at End of Treatment

    Total activity score: Day (8 am to 8 pm) at end of treatment. Accelerometer measured physical activity by monitoring degree and intensity of body motion. Data is reported as activity counts. Subject activity was collected hourly for the variables: peak, average, and total activity. Higher score indicates greater activity (no activity = 0; total possible score was not defined).

    Time frame: Week 0 to Week 2, Week 4 to Week 6 (Baseline to End of Treatment in Treatment Periods 1 and 2)

07

Results

Posted Feb 24, 2010

Participant flow

Subjects participated in the study between 05 May 2008 and 10 February 2009.

Period 1
Participant flow — Period 1
MilestonePregabalin First Then PlaceboPlacebo First Then Pregabalin
Started1312
Received study treatment1212
Completed1211
Not completed11
Withdrew: Adverse event01
Withdrew: Intolerable pain level10
Washout Period of 2 Weeks
Participant flow — Washout Period of 2 Weeks
MilestonePregabalin First Then PlaceboPlacebo First Then Pregabalin
Started1211
Completed1211
Not completed00
Period 2
Participant flow — Period 2
MilestonePregabalin First Then PlaceboPlacebo First Then Pregabalin
Started1211
Completed1211
Not completed00

Outcome measures

PrimaryChange From Baseline to Treatment Week 2 in Daily Pain Rating Scale

Daily Pain Rating Scale by treatment and sequence using an 11-point Likert scale: range 0 (no pain) to 10 (worst possible pain) over the past 24 hours. Self-assessment was performed daily on rising from bed (for the final time in the case of interrupted sleep). Average daily pain score: mean of the previous 7 days daily pain scores. Baseline was defined as the mean of the last 7 pre-treatment pain scores for each period. End of treatment was defined as the mean of the last 7 on treatment pain scores for each period.

Time frame:
Week 0 to Week 2, Week 4 to Week 6 (Baseline to Week 2 [End of Treatment] for each treatment period)
Reported as:
Mean · scores on scale
Change From Baseline to Treatment Week 2 in Daily Pain Rating Scale
scores on scalePeriod 1: PregabalinPeriod 1: PlaceboPeriod 2: PlaceboPeriod 2: Pregabalin
Baseline6.03 ± 1.295.24 ± 2.035.96 ± 0.885.31 ± 1.82
Treatment Week 25.40 ± 1.345.08 ± 2.056.11 ± 1.204.38 ± 2.02
Change from Baseline-0.63 ± 1.01-0.16 ± 0.970.16 ± 1.07-0.93 ± 1.24
Statistical analysis
  • Period 1: Pregabalin vs Period 1: Placebo vs Period 2: Placebo vs Period 2: Pregabalin · ANCOVA · Mean difference (final values): -0.81 · 80% CI -1.21 to -0.41
SecondaryNeuropathic Pain Symptom Inventory (NPSI)

NPSI at end of treatment: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.

Time frame:
Week 0 to Week 2, Week 4 to Week 6 (Baseline to End of Treatment in Treatment Periods 1 and 2)
Reported as:
Mean · scores on scale
Neuropathic Pain Symptom Inventory (NPSI)
scores on scalePregabalin/PlaceboPlacebo/Pregabalin
Week 0 (Baseline: Treatment Period 1)5.31 ± 3.505.25 ± 2.38
Week 2 (End of Treatment: Treatment Period 1)5.31 ± 3.304.91 ± 2.30
Week 4 (Baseline: Treatment Period 2)4.33 ± 3.145.27 ± 2.45
Week 6 (End of Treatment: Treatment Period 2)4.75 ± 3.393.00 ± 2.24
Statistical analysis
  • Pregabalin/Placebo vs Placebo/Pregabalin · ANCOVA · Mean difference (final values): -0.52 · 80% CI -3.82 to 2.78
SecondarySubject Activity as Captured by the Actiwatch Score Device: Total Activity Score at End of Treatment

Total activity score: Day (8 am to 8 pm) at end of treatment. Accelerometer measured physical activity by monitoring degree and intensity of body motion. Data is reported as activity counts. Subject activity was collected hourly for the variables: peak, average, and total activity. Higher score indicates greater activity (no activity = 0; total possible score was not defined).

Time frame:
Week 0 to Week 2, Week 4 to Week 6 (Baseline to End of Treatment in Treatment Periods 1 and 2)
Reported as:
Least squares mean · scores on scale
Subject Activity as Captured by the Actiwatch Score Device: Total Activity Score at End of Treatment
scores on scalePregabalinPlacebo
Subject Activity as Captured by the Actiwatch Score Device: Total Activity Score at End of Treatment300000 ± 12000270000 ± 12000
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · Mean difference (final values): 29000 · 80% CI 6100 to 51000

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—0/24 (0%)11/24 (45.8%)
Placebo—0/24 (0%)10/24 (41.7%)
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders6/241/24
NauseaGastrointestinal disorders4/243/24
HeadacheNervous system disorders3/240/24
SomnolenceNervous system disorders3/240/24
Dry mouthGastrointestinal disorders2/241/24
FatigueGeneral disorders2/241/24
VertigoEar and labyrinth disorders0/241/24
Eye disorderEye disorders1/240/24
Vision blurredEye disorders1/241/24
Abdominal painGastrointestinal disorders0/241/24

Baseline characteristics

Age, Customized
Age, Customized(years)Pregabalin Then PlaceboPlacebo Then PregabalinTotal
18 - 44 years4 ± 03 ± 07 ± 0
45 - 64 years5 ± 16.78 ± 11.813
>=65 years4 ± 01 ± 05 ± 0
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin Then PlaceboPlacebo Then PregabalinTotal
Female7714
Male6511
08

Study locations

5 sites
  • Pfizer Investigational Site
    Calgary, Alberta T2N 4N1, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Pfizer Investigational Site
    Jonkoping, 551 85, Sweden
  • Pfizer Investigational Site
    Linkoping, 581 85, Sweden
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2008
First posted
Apr 9, 2008
Start
May 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Feb 24, 2010
Last update
Feb 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00654940
Responsible party
Sponsor
First posted
Apr 9, 2008
Start date
May 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Feb 24, 2010
Last update
Feb 9, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion